Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer

MLA

Naoki Takegawa, et al. “Targeting of the HER2/HER3 Signaling Axis Overcomes Ligand‐mediated Resistance to Trastuzumab in HER2‐positive Breast Cancer.” Cancer Medicine, vol. 8, Jan. 2019, pp. 1258–68. EBSCOhost, https://doi.org/10.1002/cam4.1995.

APA

Naoki Takegawa, Hidetoshi Hayashi, Hisato Kawakami, Junji Tsurutani, Junko Tanizaki, Kazuhiko Nakagawa, Kimio Yonesaka, Satomi Watanabe, Masayuki Takeda, Koji Haratani, & Yoshikane Nonagase. (2019). Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer. Cancer Medicine, 8, 1258–1268. https://doi.org/10.1002/cam4.1995

Chicago

Naoki Takegawa, Hidetoshi Hayashi, Hisato Kawakami, Junji Tsurutani, Junko Tanizaki, Kazuhiko Nakagawa, Kimio Yonesaka, et al. 2019. “Targeting of the HER2/HER3 Signaling Axis Overcomes Ligand‐mediated Resistance to Trastuzumab in HER2‐positive Breast Cancer.” Cancer Medicine 8 (January): 1258–68. doi:10.1002/cam4.1995.